Evidence map›Paper›PMID 41756021›Full record

ArticleNeuroscience applied2026

Response to immune-based augmentation treatment for depression: a potential role of immunosenescence.

Evelien Van Assche, Christa Hohoff, Sophia M Wissing, Lea Steinbach, European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network, Bernhard T Baune

Abstract read
In one paragraph

Article in Neuroscience applied, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Evelien Van AsscheUniversity of Münster, Münster, Germany.
Christa HohoffUniversity of Münster, Münster, Germany.
Sophia M WissingUniversity of Münster, Münster, Germany.
Lea SteinbachUniversity of Münster, Münster, Germany.
European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network
Bernhard T BauneUniversity of Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunological processes are increasingly in focus as factors contributing to major depressive disorder (MDD). Especially subtypes such as immunometabolic depression phenotypes have been linked to low-grade inflammation. Augmentation with immune-based therapies, e.g., celecoxib, is being tested for its efficacy in treating depression. Many physiological processes during life are also linked to immunological changes, particularly aging. As results from current trials with celecoxib augmentation remain inconclusive, we tested the hypothesis that age affects treatment efficacy. In total, 113 individuals with a diagnosis of major depressive disorder (

Indexed as

AntidepressantAugmentationCelecoxibImmune systemImmunomethylomicsImmunosenescenceMajor depressive disorder

Identifiers

PMID41756021
PMCPMC12933617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.